Revive Therapeutics Ltd (RVVTF)

$0.02 0.00 (0.00%)

15:57 EDT RVVTF Stock Quote Delayed 30 Minutes

Find Your Next 10X Winner in the Burgeoning Shroom Boom

By Luke Lango, InvestorPlace Senior Investment Analyst Dec 3, 2020

Psychedelic stocks are going to surge as the once "hardcore" group of pschedelic drugs gains widespread mainstream medicinal acceptance.

3 Psychedelic Stocks to Buy for HUGE Gains in the Shroom Boom

3 Psychedelic Stocks Gaining More Acceptance

7 of the Best Penny Stocks to Buy Now

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.)

Day's Range -

52-Week Range $0.02 - $0.05

Dividend & Yield N/A (N/A)

RVVTF Stock Predictions, Articles, and Revive Therapeutics Ltd News

From InvestorPlace
From the Web

7 Risky Penny Stocks (That Could Really Pay Off)

By Josh Enomoto, InvestorPlace Contributor Jul 2, 2020

If you’ve got the iron stomach for volatility, these seven penny stocks could provide astounding gains amid the turmoil.

3 Penny Stocks to Buy for Psychedelic Profits

By Ian Cooper, InvestorPlace Contributor May 21, 2020

These three psychedelic penny stocks give you a massive opportunity in a trend that's shaking up the healthcare and investing worlds.

Revive says Phase 3 trial for oral COVID drug failed (OTCMKTS:RVVTF)

From Seeking Alpha Jul 6, 2023

Revive Therapeutics (RVVTF) said Thursday its Phase 3 trial for oral COVID-19 therapy Bucillamine didn’t reach statistical significance for endpoints. Read more here.

FDA asks Revive to amend main goals of phase 3 trial for COVID drug

From Seeking Alpha Mar 8, 2023

Revive Therapeutics (RVVTF) said the U.S. Food and Drug Administration ((FDA)) recommended additional revised primary symptom-based goals for a phase 3 trial of oral therapy bucillamine...

FDA opts for meeting to discuss Revive's phase 3 trial of oral COVID drug

From Seeking Alpha Nov 22, 2022

Revive Therapeutics (RVVTF) said that the U.S. Food & Drug Administration ((FDA)) recommended a Type C meeting to discuss the overall development plan and the latest revised goals of...

Revive Therapeutics: Positive Comments From The FDA Regarding Primary Endpoint Change

From Benzinga May 27, 2022

The outlook for Revive Therapeutics Ltd. (OTC: RVVTF) Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine to treat COVID-19 got a little brighter on Thursday.

Psychedelic Stock Gainers And Losers From May 26, 2022

From Benzinga May 26, 2022

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 21.06% at $0.34

TripAdvisor, Seelos Therapeutics Among Top Psychedelic Movers Of Today

From Benzinga May 25, 2022

GAINERS: TripAdvisor (NASDAQ:TRIP) shares closed up 6.06% at $23.45

ADVERTISEMENT